William Blair Analysts Boost Earnings Estimates for ALGN

Align Technology, Inc. (NASDAQ:ALGN - Free Report) - Research analysts at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for Align Technology in a report released on Thursday, May 1st. William Blair analyst B. Vazquez now expects that the medical equipment provider will post earnings of $2.28 per share for the quarter, up from their prior estimate of $2.08. The consensus estimate for Align Technology's current full-year earnings is $7.98 per share.

Align Technology (NASDAQ:ALGN - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported $2.13 EPS for the quarter, beating analysts' consensus estimates of $2.00 by $0.13. The firm had revenue of $979.26 million for the quarter, compared to analysts' expectations of $977.90 million. Align Technology had a net margin of 10.54% and a return on equity of 13.84%. The firm's revenue was down 1.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.14 EPS.

Other analysts also recently issued reports about the company. Hsbc Global Res downgraded Align Technology from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of Align Technology in a research note on Thursday. Piper Sandler reissued an "overweight" rating and issued a $250.00 price objective (up previously from $235.00) on shares of Align Technology in a research report on Thursday. Jefferies Financial Group reduced their price objective on shares of Align Technology from $285.00 to $260.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Finally, Leerink Partnrs raised shares of Align Technology from a "hold" rating to a "strong-buy" rating in a research note on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $241.25.

Align Technology Stock Performance

ALGN stock opened at $179.82 on Monday. The stock's 50 day moving average price is $168.42 and its 200 day moving average price is $200.91. The firm has a market cap of $13.16 billion, a P/E ratio of 32.05, a PEG ratio of 2.24 and a beta of 1.73. Align Technology has a 1 year low of $141.74 and a 1 year high of $291.80.

Institutional Trading of Align Technology

A number of institutional investors have recently modified their holdings of the company. Picton Mahoney Asset Management lifted its position in Align Technology by 69.9% during the fourth quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 58 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Align Technology during the 4th quarter valued at $31,000. Compagnie Lombard Odier SCmA purchased a new stake in Align Technology during the 1st quarter worth $32,000. Aster Capital Management DIFC Ltd acquired a new stake in Align Technology in the 4th quarter valued at $35,000. Finally, Center for Financial Planning Inc. purchased a new position in Align Technology in the first quarter valued at about $35,000. Hedge funds and other institutional investors own 88.43% of the company's stock.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.